Form 4: Corvus Pharmaceuticals CEO Richard Miller Acquires 750,000 Stock Options
SEC Form 4 Filing
Richard A. Miller, CEO of Corvus Pharmaceuticals, was granted 750,000 stock options on December 20, 2024, according to a Form 4 filing with the SEC.
Summary
- Richard A. Miller, the President and CEO of Corvus Pharmaceuticals, acquired 750,000 stock options on December 20, 2024.
- The options have an exercise price of $4.99.
- The options vest in equal monthly installments over three years, starting from December 20, 2024, contingent upon Miller's continued service with the company.
- The options expire on December 20, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and generally viewed as a positive sign of aligning management interests with shareholders. However, it also represents potential future dilution.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.
Stakeholder Impact
- Shareholders may experience dilution if the options are exercised.
- Employees may be motivated by the CEO's increased stake in the company's success.
Key Dates
| Date | Description |
|---|---|
| 12/20/2024 | Date of earliest transaction (grant of stock options) and start of vesting period. |
| 12/20/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.